Evaluation of Symptoms, Complications and Side Effects of Adding Medications Continuously To Subcutaneous Infusion (Hypodermoclysis) In Home Care Hospice Patients
- Conditions
- Home Infusion TherapyInfusion Pumps
- Registration Number
- NCT00320866
- Lead Sponsor
- Soroka University Medical Center
- Brief Summary
Background: Terminal patients are often unable to swallow and need medications to control symptoms. In these cases medications are administered continuously and subcutaneously by a syringe driver. A syringe driver is an expensive and sophisticated equipment to operate. Hypodermoclysis is a useful and easy alternative used in the homecare setting for hydration.
Objectives:
1. To assess the level of symptoms control by the administration of morphine, metoclopramide and midazolam by hypodermoclysis versus by a syringe driver.
2. To assess the complications and side effects of infusing these medications continuously by hypodermoclysis versus by a syringe driver.
Methods: Patients in the homecare setting who meet the criteria for parentral infusion and suffer: pain, vomit/nausea and/or agitation will be recruited for the study.
A double blind crossover methodology will be used. Each patient will serve as both intervention and control, and both patient and medical staff will be blinded to the medication route administration. A research nurse will administer the medications. Crossover will take place 48 hours thereafter. A research assistant will conduct evaluation of symptoms and side effects for a period of 4 days. A sample size of 27 patients will be included in the study (calculated for a significance level of 95% and power of 80%).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
- Patients in the home care unit that need medication/s continuously subcutaneously with symptoms level of 6 or higher on a visual analogue scale (VAS) for that symptom.
- Patients and caregivers that refuse to participate.
- Every occasion when the infusion period will be less than 48 hours.
- Every occasion when the patient and/or main care giver are not able to provide reliable information by the judgment of the medical staff person or research worker.
- Patients that will need other medications subcutaneously that are not included in the study during their study treatment period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method level of symptoms control
- Secondary Outcome Measures
Name Time Method complications and side effects
Trial Locations
- Locations (1)
Ben-Gurion University of the Negev Sial Research Center for Family Medicine and Primary Care
🇮🇱Beer Sheva, Israel